Table 1.

Suggested further reading

Ref. no	Author	Year	Topic	Description
[6]	Rochette	2015	Pathophysiology	Cardiotoxic mechanisms of anthracyclines and trastuzumab
[7]	Lenneman	2016	Pathophysiology	Overview of most common anticancer treatments and their mechanism of cardiotoxicity
[8]	Moslehi	2016	Targeted cancer therapy	Overview of cardiovascular toxicity of new targeted (non-anthracycline) cancer therapies
[9]	Curigliano	2012	Definitions/management	ESMO oncology guidelines on cardiac monitoring, referral, and therapy
[10]	Christenson	2015	Early detection Biomarkers	Overview of circulating biomarkers in predicting chemotherapy-induced cardiac toxicity
[11]	Thavendiranathan	2014	Early detection Echocardiography	Echocardiographic myocardial deformation in the early detection of cardiotoxicity
[12]	Thavendiranathan	2013	Early detection CMR	The role of cardiac magnetic resonance in the detection of cardiotoxicity
[13]	Plana	2014	Imaging	ESC position paper on non-invasive imaging modalities in cardio-oncology
[14]	Herrmann	2014	Risk stratification and management	Practical aspects regarding cardio-oncology care, including an outline of a risk assessment tool
[15]	Zamorano	2016	Risk stratification and management	ESC position paper on cancer treatments and cardiovascular toxicity
[16]	Lancellotti	2013	Radiotherapy	Consensus paper on imaging and management of cardiovascular complications of radiotherapy
[5]	Naaktgeboren	2017	Long-term outcome	Overview on long-term outcome after anticancer treatment (chemo- and radiotherapy)
[17]	Dalen	2011	Prevention	Cochrane review on cardioprotective interventions for cancer patients receiving anthracyclines
[18]	Kalam	2013	Prevention	Systematic review on cardioprotective therapy for prevention of cardiotoxicity with chemotherapy
[19]	Johnson	2017	Training	Paper exploring training programs for medical specialists in cardio-oncology